ACS Medicinal Chemistry Letters
Page 6 of 8
1
3y*
H
>20
>20
>20
>20
>20
1
2
3
4
5
6
7
8
9
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
1
3z*
0.71
3.4
a
2
b
c
d
All r values >0.75. All SEM values within 25%. n=1. n=2. *Isolated as a side product.
Wilmot, K.; Pollastri, M. P., Kinase scaffold repurposing
REFERENCES
Moran, M.; Guzman, J.; Ropars, A.-L.;
McDonald, A.; Jameson, N.; Omune, B.; Ryan, S.; Wu, L.,
Neglected Disease Research and Development: How Much
Are We Really Spending? PLOS Med. 2009, 6, e1000030.
World Health Organization Investing to overcome
the global impact of neglected tropical diseases: Third
WHO report on neglected tropical diseases; 2015.
for neglected disease drug discovery: discovery of an
efficacious, lapatinib-derived lead compound for
trypanosomiasis. J. Med. Chem. 2013, 56, 3820-3832.
1
.
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
4.
Devine, W.; Woodring, J. L.; Swaminathan, U.;
Amata, E.; Patel, G.; Erath, J.; Roncal, N. E.; Lee, P. J.;
Leed, S. E.; Rodriguez, A.; Mensa-Wilmot, K.; Sciotti, R.
J.; Pollastri, M. P., Protozoan Parasite Growth Inhibitors
Discovered by Cross-Screening Yield Potent Scaffolds for
Lead Discovery. J. Med. Chem. 2015, 58, 5522-5537.
2
.
3
.
Simarro, P. P.; Cecchi, G.; Franco, J. R.; Paone,
M.; Diarra, A.; Ruiz-Postigo, J. A.; Fevre, E. M.; Mattioli,
R. C.; Jannin, J. G., Estimating and mapping the population
at risk of sleeping sickness. PLoS Negl. Trop. Dis. 2012, 6,
e1859.
1
5.
Katiyar, S.; Kufareva, I.; Behera, R.; Thomas, S.
M.; Ogata, Y.; Pollastri, M.; Abagyan, R.; Mensa-Wilmot,
K., Lapatinib-Binding Protein Kinases in the African
Trypanosome: Identification of Cellular Targets for
Kinase-Directed Chemical Scaffolds. PLoS One 2013, 8,
e56150.
Karen, E. L., Lessons from the Drug Discovery of
Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor. Curr.
Top. Med. Chem. 2006, 6, 435-460.
4
.
Alvar, J.; Velez, I. D.; Bern, C.; Herrero, M.;
Desjeux, P.; Cano, J.; Jannin, J.; den Boer, M.; Team, W.
H. O. L. C., Leishmaniasis worldwide and global estimates
of its incidence. PLoS One 2012, 7, e35671.
1
6.
5
.
de Souza, A.; Ishikawa, E.; Braga, R.; Silveira, F.;
Lainson, R.; Shaw, J., Psychodopygus complexus, a new
vector of Leishmania braziliensis to humans in Para State,
Brazil. Trans. Royal Soc. Trop. Med. Hyg. 1996, 90, 112-
113.
Andrade, L. O.; Andrews, N. W., The
Trypanosoma cruzi-host-cell interplay: location, invasion,
1
7.
Parsons, M.; Worthey, E. A.; Ward, P. N.;
Mottram, J. C., Comparative analysis of the kinomes of
three pathogenic trypanosomatids: Leishmania major,
Trypanosoma brucei and Trypanosoma cruzi. BMC Genom.
005, 6, 1-19.
8. Shultz, M. D.; Cheung, A. K.; Kirby, C. A.;
Firestone, B.; Fan, J.; Chen, C. H.; Chen, Z.; Chin, D. N.;
Dipietro, L.; Fazal, A.; Feng, Y.; Fortin, P. D.; Gould, T.;
Lagu, B.; Lei, H.; Lenoir, F.; Majumdar, D.; Ochala, E.;
Palermo, M. G.; Pham, L.; Pu, M.; Smith, T.; Stams, T.;
Tomlinson, R. C.; Toure, B. B.; Visser, M.; Wang, R. M.;
Waters, N. J.; Shao, W., Identification of NVP-TNKS656:
The Use of Structure-Efficiency Relationships To Generate
a Highly Potent, Selective, and Orally Active Tankyrase
Inhibitor. J. Med. Chem. 2013, 56, 6495-6511.
Hopkins, A. L.; Groom, C. R.; Alex, A., Ligand
efficiency: a useful metric for lead selection. Drug Discov.
Today 2004, 9, 430-431.
Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P.
A., The maximal affinity of ligands. Proc. Nat. Acad. Sci.
1999, 96, 9997-10002.
6.
2
1
retention. Nat. Rev. Microbiol. 2005, 3, 819-823.
7.
Chulay, J. D.; Spencer, H. C.; Mugambi, M.,
Electrocardiographic changes during treatment of
leishmaniasis with pentavalent antimony (sodium
stibogluconate). Am. J. Trop. Med. Hyg. 1985, 34, 702-709.
8.
Delgado, J.; Macias, J.; Pineda, J. A.; Corzo, J. E.;
Gonzalez-Moreno, M. P.; de la Rosa, R.; Sanchez-Quijano,
A.; Leal, M.; Lissen, E., High frequency of serious side
effects from meglumine antimoniate given without an
upper limit dose for the treatment of visceral leishmaniasis
in human immunodeficiency virus type-1-infected patients.
Am. J. Trop. Med. Hyg. 1999, 61, 766-769.
1
9.
9.
for treating leishmaniasis with sodium stibogluconate
Pentostam) and review of pertinent clinical studies. Am. J.
Trop. Med. Hyg. 1992, 46, 296-306.
0. Chappuis, F.; Sundar, S.; Hailu, A.; Ghalib, H.;
Herwaldt, B. L.; Berman, J. D., Recommendations
2
0.
(
21.
Leeson, P. D.; Springthorpe, B., The influence of
drug-like concepts on decision-making in medicinal
chemistry. Nat. Rev. Drug Discov. 2007, 6, 881-890.
1
Rijal, S.; Peeling, R. W.; Alvar, J.; Boelaert, M., Visceral
leishmaniasis: what are the needs for diagnosis, treatment
and control? Nat. Rev. Microbiol. 2007, 5, 873-882.
22.
generation. Exp. Opin. Drug Discov. 2015, 10, 781-790.
23. Welsch, M. E.; Snyder, S. A.; Stockwell, B. R.,
Zhao, H.; Dietrich, J., Privileged scaffolds in lead
1
1.
leishmaniasis. J. Biomed. Biotechnol. 2010, 2010, 617521.
2. Messori, A.; Fadda, V.; Maratea, D.; Trippoli, S.;
Maltezou, H. C., Drug resistance in visceral
Privileged scaffolds for library design and drug discovery.
Curr. Op. Chem. Bio. 2010, 14, 347-361.
1
Marinai, C., Nephrotoxicity of different formulations of
amphotericin B: summarizing evidence by network meta-
analysis. Clin. Infect. Dis. 2013, 57, 1783-1784.
Patel, G.; Karver, C. E.; Behera, R.; Guyett, P. J.;
Sullenberger, C.; Edwards, P.; Roncal, N. E.; Mensa-
24.
Bongarzone, S.; Bolognesi, M. L., The concept of
privileged structures in rational drug design: focus on
acridine and quinoline scaffolds in neurodegenerative and
protozoan diseases. Exp. Opin. Drug Discov. 2011, 6, 251-
1
3.
2
68.
ACS Paragon Plus Environment